Its technology came out of Stanford University and led to its GeneRide tech platform. LogicBio Therapeutics is a genome editing company, founded to deliver the benefits of genome editing to the fight against early onset childhood diseases. The gene-editing system CRISPR is the hottest subject in biology because of the technique’s ability to change DNA letters and potentially cure genetic disease. The article Gene editing biotech LogicBio files for a $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com. The collaboration will bring together LogicBio’s propriety platform for genome editing and Takeda’s expertise in researching and developing gene therapies. The article Gene editing biotech LogicBio Therapeutics sets terms for $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com. Its technology came out of Stanford University and led to its GeneRide tech platform. Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children.
www.logicbio.com. Launched in 2016 by pioneers in gene therapy from Stanford University and funded by leading life science investors, LogicBio is developing a pipeline of … Based in Cambridge, Mass., LogicBio focuses on gene therapy and gene editing. Website. Based in Cambridge, Mass., LogicBio focuses on gene therapy and gene editing.
... Fred Chereau.
CAMBRIDGE - LogicBio Therapeutics, Inc. , a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients today announced a research collaboration with... | January 13, 2020 This platform is designed to integrate corrective genes into a patient’s genome in a precise and stable way, using a natural DNA repair process called homologous recombination.